Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 24 March (HL15339), whether they have plans to discuss with the charity Anthony Nolan the potential for children and young people with non-malignant conditions, who travel long distances to receive stem cell transplants and chimeric antigen receptor T-cell therapy, to be included in the new travel cost scheme.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Through the National Cancer Plan for England, the Government is committing up to £10 million a year to a new fund open to all children and young people in England with cancer and their families regardless of income, to support them with the cost of travelling to and from their treatment. This commitment sits alongside wider action to transform cancer care for children and young people.

The Department is currently working with its partners to define the scope and parameters of the scheme and further detail will be announced in due course.

Currently, the National Health Service runs schemes in England to provide financial assistance for travel to a hospital or other NHS premises for specialist treatment or diagnostics tests, following referral from a primary healthcare professional. The Healthcare Travel Costs Scheme provides financial assistance to patients in England who do not have a medical need for transport, but who require assistance with the costs of travelling to receive certain NHS services. The Non-Emergency Patient Transport Services provide funded transport where it is considered essential to ensuring an individual’s safety, safe mobilisation, condition management, or recovery.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 4 March (HL14721) indicating a substantial underspend in the Innovative Medicines Fund, what steps they are taking to expand managed access pathways for innovative medicines, including disease-modifying treatments for Alzheimer’s disease such as Lecanemab and Donanemab.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England cannot comment on the proportion of the Innovative Medicines Fund’s budget that has been spent on medicines made available through managed access agreements. Due to the low numbers of patients who receive these highly specialised treatments, publishing this information risks confidentiality of pricing.

The National Institute for Health and Care Excellence (NICE) is able to recommend any medicine, including for the treatment of Alzheimer’s disease, for a period of managed access through the Innovative Medicines Fund where it concludes that it is plausibly cost effective and the collection of real-world evidence may resolve clinical uncertainty. NICE concluded in its draft guidance on lecanemab and donanemab that neither treatment was suitable for a period of managed access but has not yet published its final guidance. There are no current plans to expand the circumstances in which NICE is able recommend medicines for managed access.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 4 March (HL14721), what proportion of the Innovative Medicines Fund budget has been spent on medicines made available through managed access agreements.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England cannot comment on the proportion of the Innovative Medicines Fund’s budget that has been spent on medicines made available through managed access agreements. Due to the low numbers of patients who receive these highly specialised treatments, publishing this information risks confidentiality of pricing.

The National Institute for Health and Care Excellence (NICE) is able to recommend any medicine, including for the treatment of Alzheimer’s disease, for a period of managed access through the Innovative Medicines Fund where it concludes that it is plausibly cost effective and the collection of real-world evidence may resolve clinical uncertainty. NICE concluded in its draft guidance on lecanemab and donanemab that neither treatment was suitable for a period of managed access but has not yet published its final guidance. There are no current plans to expand the circumstances in which NICE is able recommend medicines for managed access.